Literature DB >> 1697306

Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice by using a peptide with high affinity for IAs molecules.

A G Lamont1, A Sette, R Fujinami, S M Colón, C Miles, H M Grey.   

Abstract

Blocking of the Ag presenting function of MHC by peptides capable of high affinity binding to this molecule has been proposed as a potential immunotherapeutic intervention in MHC-associated diseases. Recent studies have used this strategy to prevent the induction of experimental allergic encephalomyelitis (EAE) in mice. However, because of the close structural relationship between the inhibitor and encephalitogenic peptides, the results of these previous studies have been difficult to interpret with regard to whether MHC blockade was the mechanism by which the inhibitory peptides functioned. In our study, we have determined the capacity of unrelated peptides capable of binding with high affinity to IAs in inhibiting the induction of EAE in SJL/J mice after immunization with the autoantigenic peptide PLP 139-151. Prevention of the disease was accomplished by two methods: 1) when inhibitor was administered together with the encephalitogenic peptide at the time of immunization, as in previous studies, and 2) when inhibitor was administered at a separate site from the autoantigen 1 day before the immunization with that Ag. Inhibition was due to binding of the inhibitor to IAs, as evidenced by the fact that a control peptide incapable of binding to this MHC had no effect on the course of the disease. The finding that inhibitor could also be efficacious when administered at a separate site has implications for potential use of such a strategy to reverse ongoing autoimmune diseases. The inhibitor had to be present during the time of Ag stimulation, and had no long term inhibitory effects, in that a secondary immune response to the encephalitogenic peptide was not inhibited in animals given the inhibitory peptide before the induction of a primary response. This is compatible with the conclusion that MHC blockade was, in fact, the mechanism of the inhibition, rather than as a result of any long term suppressive effects on immunoreactive T cells. Finally, not only did administration of the inhibitory peptide lead to a prevention of the induction of EAE, but it could also be shown to decrease the T cell proliferative response in vitro to the autoantigen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697306

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Design of high-affinity major histocompatibility complex-specific antagonist peptides that inhibit cytotoxic T-lymphocyte activity: implications for control of viral disease.

Authors:  J E Gairin; M B Oldstone
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

Review 2.  A role for major histocompatibility complex-binding peptides in the immunotherapy of autoimmune disease.

Authors:  D C Wraith; D E Smilek
Journal:  Springer Semin Immunopathol       Date:  1992

Review 3.  Approaches toward peptide-based immunotherapy of autoimmune diseases.

Authors:  L Adorini; J C Guéry; S Trembleau
Journal:  Springer Semin Immunopathol       Date:  1992

4.  A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens.

Authors:  L B Nicholson; A Murtaza; B P Hafler; A Sette; V K Kuchroo
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

5.  A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis.

Authors:  D E Smilek; D C Wraith; S Hodgkinson; S Dwivedy; L Steinman; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

6.  Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.

Authors:  R Aharoni; D Teitelbaum; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

Review 7.  Modulation of the immune response with T-cell epitopes: the ultimate goal for specific immunotherapy of autoimmune disease.

Authors:  P J Fairchild; C J Thorpe; P J Travers; D C Wraith
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

Review 8.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

9.  Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs.

Authors:  Y Katz-Levy; S L Kirshner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

10.  Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones.

Authors:  M Fridkis-Hareli; E F Rosloniec; L Fugger; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.